APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 1.5mg capsule bottle

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

rivastigmine hydrogen tartrate, Quantity: 2.4 mg

Pieejams no:

Arrotex Pharmaceuticals Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

rivastigmine hydrogen tartrate

Zāļu forma:

Capsule

Kompozīcija:

Excipient Ingredients: titanium dioxide; stearic acid; iron oxide yellow; maize starch; Gelatin; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Ievadīšanas:

Oral

Vienības iepakojumā:

100, 56, 500

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Produktu pārskats:

Visual Identification: Hard gelatine calsule with yellow, opaque body and yellow opaque cap. Imprinted "APO R1.5" in black ink, white to off white fill.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorizācija statuss:

Licence status A

Autorizācija datums:

2010-07-27